AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17720075 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmic review 2 hours after surgery and 2 weeks postoperatively (Group 1)
Number of subjects: 233
Study 17720075 — intervention group
Group type: COMPARATOR
Intervention: No ophthalmic review before the 2-week postoperative visit (Group 2)
Number of subjects: 233
Study 15205753 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical registries
Number of subjects: 0
Study 15205753 — intervention group
Group type: COMPARATOR
Intervention: Randomized clinical trials
Number of subjects: 0
Study 11092494 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnevist (dimeglumine gadopentetate)
Number of subjects: 2049
Study 11092494 — intervention group
Group type: COMPARATOR
Intervention: Omniscan (gadodiamide)
Number of subjects: 2049
Study 9351750 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocervical brush
Number of subjects: 118
Study 9351750 — intervention group
Group type: COMPARATOR
Intervention: Curette (Control)
Number of subjects: 118
Study 8212148 — intervention group
Group type: EXPERIMENTAL
Intervention: University of Wisconsin (UW) solution
Number of subjects: 14
Study 8212148 — intervention group
Group type: COMPARATOR
Intervention: Hyperosmolar citrate (HOC)
Number of subjects: 14
Study 3513304 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 131
Study 28376498 — intervention group
Group type: EXPERIMENTAL
Intervention: HG-sPFTC patients
Number of subjects: 22
Study 28376498 — intervention group
Group type: COMPARATOR
Intervention: HG-sEOC patients
Number of subjects: 22
Study 25922136 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance check-ups (MCUs)
Number of subjects: 74
Study 25922136 — intervention group
Group type: COMPARATOR
Intervention: No check-up (NCU)
Number of subjects: 74
Study 23760999 — intervention group
Group type: EXPERIMENTAL
Intervention: Group led by vocational staff using the vocational manual
Number of subjects: 111
Study 23760999 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-study using a vocational manual
Number of subjects: 111
Study 23760999 — intervention group
Group type: COMPARATOR
Intervention: Basic vocational services
Number of subjects: 111
Study 21669540 — intervention group
Group type: EXPERIMENTAL
Intervention: 180-minute group HIV risk-reduction counseling intervention
Number of subjects: 160
Study 21669540 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 160
Study 21669540 — intervention group
Group type: EXPERIMENTAL
Intervention: Both experimental and control groups
Number of subjects: 160
Study 19621708 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV)
Number of subjects: 52
Study 19621708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 16447933 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable cutting head at high speed
Number of subjects: 51
Study 16447933 — intervention group
Group type: COMPARATOR
Intervention: Nondisposable cutting head at low speed
Number of subjects: 51
Study 16447933 — intervention group
Group type: COMPARATOR
Intervention: Disposable cutting head at low speed
Number of subjects: 51
Study 16447933 — intervention group
Group type: COMPARATOR
Intervention: Nondisposable cutting head at high speed
Number of subjects: 51
Study 15003298 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 20mg subcutaneous injection once daily for 3 weeks
Number of subjects: 120
Study 15003298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 11555219 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative virtual patient model
Number of subjects: 2
Study 11555219 — intervention group
Group type: COMPARATOR
Intervention: Problem-solving virtual patient model
Number of subjects: 2
Study 11555219 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline performance)
Number of subjects: 2
Study 9543364 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisone (5 mg/kg per day in four oral doses over 7 days)
Number of subjects: 92
Study 9543364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 7995913 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound attenuation measurement of calcaneum bone density
Number of subjects: 107
Study 7995913 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound attenuation measurement of lumbar vertebrae bone density
Number of subjects: 107
Study 7995913 — intervention group
Group type: COMPARATOR
Intervention: Reference values from Walker Sonics machine
Number of subjects: 107
Study 7995913 — intervention group
Group type: COMPARATOR
Intervention: Quantitative densitometry with computed tomography
Number of subjects: 107
Study 3291099 — intervention group
Group type: EXPERIMENTAL
Intervention: Timegadine 500 mg/day
Number of subjects: 40
Study 3291099 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 750 mg/day
Number of subjects: 40
Study 31093719 — intervention group
Group type: EXPERIMENTAL
Intervention: IVC filters
Number of subjects: 39056
Study 28485008 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnosine as adjuvant to fluvoxamine
Number of subjects: 44
Study 28485008 — intervention group
Group type: COMPARATOR
Intervention: Placebo as adjuvant to fluvoxamine
Number of subjects: 44
Study 25212871 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg for the first day, 75 mg/day thereafter) plus aspirin (100 mg/day)
Number of subjects: 690
Study 25212871 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (300 mg/day)
Number of subjects: 690
Study 25212871 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 690
Study 25212871 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 690
Study 24377217 — intervention group
Group type: EXPERIMENTAL
Intervention: Jin's three-needle therapy
Number of subjects: 100
Study 24377217 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation therapy
Number of subjects: 100
Study 24377217 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (acupuncture and rehabilitation)
Number of subjects: 100
Study 24377217 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Jin's three-needle, rehabilitation, combined therapy)
Number of subjects: 100
Study 21953629 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 12
Study 21953629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19501656 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture with high expectancy
Number of subjects: 48
Study 19501656 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture with low expectancy
Number of subjects: 48
Study 19501656 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 48
Study 19501656 — intervention group
Group type: EXPERIMENTAL
Intervention: All four groups (including verum and control)
Number of subjects: 48
Study 16995460 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic band ligation and propranolol
Number of subjects: 72
Study 16995460 — intervention group
Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 72
Study 14988282 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported energy intake (EI)
Number of subjects: 200
Study 14988282 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy underreporters
Number of subjects: 200
Study 14988282 — intervention group
Group type: EXPERIMENTAL
Intervention: EI-to-TEE ratio
Number of subjects: 200
Study 14988282 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic variables, BMI, and following a diet for diabetes
Number of subjects: 200
Study 11246353 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 L of PEG‐ELS with 20 mg bisacodyl
Number of subjects: 68
Study 11246353 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 L of PEG‐ELS preceded by 296 mL of magnesium citrate
Number of subjects: 68
Study 11246353 — intervention group
Group type: COMPARATOR
Intervention: 4 L of PEG‐ELS
Number of subjects: 68
Study 9141518 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-386 0.1 mg
Number of subjects: 100
Study 9141518 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-386 0.5 mg
Number of subjects: 100
Study 9141518 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-386 5 mg
Number of subjects: 100
Study 9141518 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-386 20 mg
Number of subjects: 100
Study 9141518 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-386 50 mg
Number of subjects: 100
Study 9141518 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg
Number of subjects: 100
Study 8153915 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (administered continuously for 48 hours after surgery)
Number of subjects: 37
Study 8153915 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (administered for 24 hours after cholecystectomy)
Number of subjects: 37
Study 8153915 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group, administered for 24 hours after cholecystectomy)
Number of subjects: 37
Study 3528979 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone
Number of subjects: 50
Study 3528979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31479537 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent quality improvement intervention including non‐physician care coordinators and clinical decision‐support software
Number of subjects: 0
Study 31479537 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 31479537 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent quality improvement intervention
Number of subjects: 0
Study 30346655 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk powder co-supplemented with inulin and resistant dextrin (MPCIR)
Number of subjects: 0
Study 26432031 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Counselling (IPC), 7 sessions
Number of subjects: 40
Study 26432031 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT), 16 sessions
Number of subjects: 40
Study 25614600 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion (2 μg·min(‐1)·kg(‐1)) at rest
Number of subjects: 21
Study 25614600 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (100% oxygen) at rest
Number of subjects: 21
Study 25614600 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion during handgrip (HG) exercise
Number of subjects: 21
Study 25614600 — intervention group
Group type: COMPARATOR
Intervention: Handgrip (HG) exercise
Number of subjects: 21
Study 23940227 — intervention group
Group type: EXPERIMENTAL
Intervention: DA (daunorubicin and cytarabine)
Number of subjects: 1983
Study 23940227 — intervention group
Group type: COMPARATOR
Intervention: ADE (daunorubicin, cytarabine, etoposide)
Number of subjects: 1983
Study 23940227 — intervention group
Group type: COMPARATOR
Intervention: FLAG-Ida (fludarabine, cytarabine, G-CSF, idarubicin)
Number of subjects: 1983
Study 23940227 — intervention group
Group type: EXPERIMENTAL
Intervention: MACE-MidAC (amsacrine, cytarabine, etoposide, mitoxantrone/cytarabine)
Number of subjects: 1983
Study 23940227 — intervention group
Group type: COMPARATOR
Intervention: High-dose cytarabine (1.5 g/m2 or 3 g/m2)
Number of subjects: 1983
Study 23940227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine (1.5 g/m2)
Number of subjects: 1983
Study 23940227 — intervention group
Group type: EXPERIMENTAL
Intervention: Fifth course (cytarabine)
Number of subjects: 1983
Study 23940227 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAG-Ida (two courses) and cytarabine (two courses)
Number of subjects: 1983
Study 22314671 — intervention group
Group type: EXPERIMENTAL
Intervention: Acu-TENS
Number of subjects: 44
Study 18340256 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive short-term dynamic psychotherapy (ISTDP)
Number of subjects: 27
Study 18340256 — intervention group
Group type: COMPARATOR
Intervention: Minimal-contact, delayed-treatment control condition
Number of subjects: 27
Study 17154774 — intervention group
Group type: EXPERIMENTAL
Intervention: Tone discrimination task
Number of subjects: 0
Study 17154774 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading aloud task
Number of subjects: 0
Study 17154774 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthographic neighborhood density
Number of subjects: 0
Study 12665158 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrocodeine (60 mg single dose)
Number of subjects: 9
Study 11194454 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyadenylic-polyuridylic acid plus locoregional radiotherapy
Number of subjects: 517
Study 11194454 — intervention group
Group type: COMPARATOR
Intervention: CMF (Control)
Number of subjects: 517
Study 9151543 — intervention group
Group type: EXPERIMENTAL
Intervention: Various concurrent recruitment methods
Number of subjects: 0
Study 9151543 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular monitoring of recruitment efficiency
Number of subjects: 0
Study 9151543 — intervention group
Group type: EXPERIMENTAL
Intervention: Careful planning and attention to product design and staff training
Number of subjects: 0
Study 9151543 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex trial designs (e.g., pre-randomization placebo run-in, split-mouth designs)
Number of subjects: 0
Study 8400972 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone + 1 mg gemeprost
Number of subjects: 1182
Study 8400972 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg mifepristone + 1 mg gemeprost
Number of subjects: 1182
Study 8400972 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg mifepristone + 1 mg gemeprost
Number of subjects: 1182
Study 2448908 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable drainage system
Number of subjects: 0
Study 2448908 — intervention group
Group type: COMPARATOR
Intervention: Glass drainage system
Number of subjects: 0
Study 31654548 — intervention group
Group type: EXPERIMENTAL
Intervention: Human fibrinogen concentrate (HFC; 4 g)
Number of subjects: 43
Study 31654548 — intervention group
Group type: COMPARATOR
Intervention: Cryoprecipitate (two pools of 5 units, approximately 4.0-4.6 g fibrinogen)
Number of subjects: 43
Study 28222627 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once daily
Number of subjects: 388
Study 28222627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg three times daily
Number of subjects: 388
Study 28222627 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 388
Study 28222627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 388
Study 28222627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study 26354542 — intervention group
Group type: EXPERIMENTAL
Intervention: Improving dietary quality (increased fruit by +1 serving; 150 g/d, vegetables by +2 servings; 150 g/d, and dairy by +1 serving; 200-250 g/d)
Number of subjects: 118
Study 26354542 — intervention group
Group type: EXPERIMENTAL
Intervention: Improving dietary quality (increased fruit and vegetable intake)
Number of subjects: 118
Study 26354542 — intervention group
Group type: EXPERIMENTAL
Intervention: Improving dietary quality (yogurt intake)
Number of subjects: 118
Study 26354542 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual diet)
Number of subjects: 118
Study 23026870 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture treatment
Number of subjects: 130
Study 23026870 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture treatment
Number of subjects: 130
Study 20354496 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume zero-balanced ultrafiltration (35 mL/kg)
Number of subjects: 40
Study 20354496 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 18207289 — intervention group
Group type: EXPERIMENTAL
Intervention: LGT/DEN4 vaccine (10^3 PFU)
Number of subjects: 28
Study 18207289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 16607233 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa, 40,000 IU, administered subcutaneously once weekly (n=48)
Number of subjects: 73
Study 16607233 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=25)
Number of subjects: 73
Study 16607233 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 73
Study 16607233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 14603056 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral pharyngoplasty
Number of subjects: 10
Study 12869080 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of oral baclofen
Number of subjects: 11
Study 12869080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 11798621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 212
Study 11798621 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin
Number of subjects: 212
Study 8605131 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate (3.6 mg subcutaneously)
Number of subjects: 160
Study 8605131 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate (3.6 mg subcutaneously) for 8 weeks
Number of subjects: 160
Study 8605131 — intervention group
Group type: COMPARATOR
Intervention: Both treatment regimens (Goserelin and Danazol)
Number of subjects: 160
Study 1857247 — intervention group
Group type: EXPERIMENTAL
Intervention: Check-box format
Number of subjects: 547
Study 1857247 — intervention group
Group type: COMPARATOR
Intervention: Open-ended questions
Number of subjects: 547
Study 6355421 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (0.5, 1.0, and 2.0 mg/kg)
Number of subjects: 10
Study 6355421 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (after 1 week of treatment)
Number of subjects: 10
Study 6355421 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril combined with hydrochlorothiazide
Number of subjects: 10
Study 6355421 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 10
Study 6355421 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril clearance
Number of subjects: 10
Study 3987782 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin once daily
Number of subjects: 20
Study 3987782 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin twice daily
Number of subjects: 20
Study 3987782 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 30081390 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus twice-weekly medication reminders by SMS (n=62)
Number of subjects: 132
Study 30081390 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU; n=70)
Number of subjects: 132
Study 30081390 — intervention group
Group type: COMPARATOR
Intervention: TAU (n=70)
Number of subjects: 132
Study 26565928 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) program, 7-week duration
Number of subjects: 52
Study 26565928 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study 26401779 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (100 mg/day)
Number of subjects: 65
Study 26401779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 23818206 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM)
Number of subjects: 94
Study 23818206 — intervention group
Group type: COMPARATOR
Intervention: Montelukast tablets and theophylline
Number of subjects: 94
Study 21426747 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (uvulopalatopharyngoplasty)
Number of subjects: 382
Study 18679092 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryan cervical disc prosthesis (n=242)
Number of subjects: 463
Study 18679092 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion with an anterior cervical plate (n=221)
Number of subjects: 463
Study 17132970 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg per day)
Number of subjects: 0
Study 17132970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17132970 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 0
Study 12828502 — intervention group
Group type: EXPERIMENTAL
Intervention: SLI‐381 10, 20 or 30mg once daily
Number of subjects: 563
Study 12828502 — intervention group
Group type: EXPERIMENTAL
Intervention: SLI‐381
Number of subjects: 563
Study 12828502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 563
Study 10866908 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion at 10 mL/h (Group 1)
Number of subjects: 45
Study 10866908 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion at 5 mL/h plus PCA boluses (2.5 mL/30 min) (Group 2)
Number of subjects: 45
Study 10866908 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA boluses only (10 mL/60 min) (Group 3)
Number of subjects: 45
Study 10866908 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 45
Study 9103270 — intervention group
Group type: EXPERIMENTAL
Intervention: Brussels sprouts (300 g per day)
Number of subjects: 10
Study 9103270 — intervention group
Group type: COMPARATOR
Intervention: Glucosinolate-free vegetables (300 g per day)
Number of subjects: 10
Study 8403942 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen
Number of subjects: 52
Study 8403942 — intervention group
Group type: COMPARATOR
Intervention: ASA plus dipyridamole
Number of subjects: 52
Study 3095082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin 10 mg
Number of subjects: 12
Study 3095082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin 20 mg
Number of subjects: 12
Study 3095082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3095082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin (10 mg and 20 mg)
Number of subjects: 12
Study 31515632 — intervention group
Group type: EXPERIMENTAL
Intervention: NZBC extract (600 mg day-1 CurraNZ™ containing 210 mg anthocyanins)
Number of subjects: 18
Study 31515632 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study 31515632 — intervention group
Group type: EXPERIMENTAL
Intervention: NZBC extract
Number of subjects: 18